Silence Therapeutics plc develops siRNA therapies through its proprietary mRNAi GOLD platform and trades in the U.S. through American Depositary Shares under SLN. Company news commonly covers clinical and preclinical updates for RNA-silencing programs in cardiovascular disease, hematology and rare diseases, along with financial results, research presentations and collaboration activity.
Recurring pipeline coverage centers on divesiran, a wholly owned siRNA candidate targeting TMPRSS6 for polycythemia vera, including SANRECO study updates and its FDA Fast Track and Orphan Drug designations. Updates also address platform-derived programs such as SLN312, AstraZeneca collaboration matters, balance-sheet commentary and board or executive changes.
Silence Therapeutics presented positive pre-clinical data for SLN360 at the American Heart Association's 2020 conference. The data reveals no adverse effects, demonstrating safe biodistribution primarily in the liver and kidneys. SLN360 targets elevated lipoprotein(a), a genetic risk factor for cardiovascular diseases, and is set to enter in-human testing following promising results. The ongoing Phase I APOLLO trial aims to assess safety and efficacy in patients with elevated Lp(a) levels, potentially offering a novel treatment for this unmet medical need.
Silence Therapeutics (AIM:SLN, Nasdaq:SLN) has announced a significant change in its executive leadership, initiating a search for a U.S.-based Chief Financial Officer (CFO). Current CFO Rob Quinn will transition from the role in January 2021 to pursue a new opportunity. This change follows Silence's recent Nasdaq listing aimed at enhancing its U.S. market presence and engagements with investors. Mark Rothera, the CEO, emphasized this strategy to leverage U.S. growth potential, and Iain Ross, the Chairman, acknowledged the strong position left by Quinn.